ArticleTranslational lung cancer research2023
Rhabdomyolysis in a patient with advanced lung cancer treated with osimertinib: a case report.
Article in Translational lung cancer research, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed, 8 citations in OpenAlex.
- The Incidence, Severity and Risk Factors of Renal Injury in Lung Cancer Patients Receiving Osimertinib Therapy: A Real-World Study.Cancer medicine · 2025Article
- Lung cancer in non-smoking women (LCINSW): from risk factors to precision therapy.Cancer metastasis reviews · 2025Review
- Osimertinib-related myotoxicity: a disproportionality analysis of the FDA adverse event reporting system.BMC cancer · 2025Article
- Lazertinib-Induced Rhabdomyolysis in a Patient With Non-Small Cell Lung Cancer: A Case Report.Respirology case reports · 2025Article
- Serum creatine kinase elevation following tyrosine kinase inhibitor treatment in cancer patients: Symptoms, mechanism, and clinical management.Clinical and translational science · 2024Review
- Article
- Adverse event profile differences between pralsetinib and selpercatinib: a real-world study based on the FDA adverse events reporting system.Frontiers in pharmacology · 2024Article
- Nephrotoxicity of targeted therapy used to treat lung cancer.Frontiers in immunology · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: As a third-generation epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI), osimertinib is the standard treatment for patients with Case Description: Herein, we present a 70-year-old non-smoking woman diagnosed with metastatic lung adenocarcinoma harboring an Conclusions: This is the first report of osimertinib-associated RM during the treatment of a lung adenocarcinoma patient. Although osimertinib-associated RM is rare, it is worthy of clinical attention in clinical practice, especially in patients receiving osimertinib plus bevacizumab. Once developed myalgia, muscular weakness and tea-colored urine, laboratory tests including serum creatine kinase (CK) and myoglobin (Mb) levels must be done, also osimertinib should be timely withdrawn to identify the cause.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.